For decades, pancreatic cancer has occupied a particular place in medicine's shadow — a disease so reliably fatal that oncologists have learned to measure hope in weeks rather than years. At a major oncology conference in Chicago, results from a trial of daraxonrasib, a targeted therapy developed by Revolution Medicines, offered something the field had not encountered before: patients living nearly twice as long as those on standard chemotherapy. In a disease where the five-year survival rate barely reaches ten percent, this is not merely a statistical milestone — it is a renegotiation of what
Daraxonrasib nearly doubles survival in pancreatic cancer, marking breakthrough
Pancreatic cancer remains one of the deadliest cancers with historically poor survival outcomes; this breakthrough offers hope for improved patient survival and quality of life.
This is such an incredibly impactful study for our patients.
Mark
Why does this particular result seem to have hit oncologists so hard? There have been other drug approvals.
Mimi
Pancreatic cancer has been a graveyard for hope. Doctors have been using the same chemotherapy regimen for years with minimal improvement. To suddenly see survival nearly double—that's not incremental progress. That's a rupture.
Mark
But it's still a trial result. What happens next?
Mimi
Regulatory review. If the FDA approves it, then the question becomes access—cost, insurance coverage, which patients get it first. The emotional breakthrough in the clinic is real, but it doesn't automatically translate to every patient who needs it.
Mark
The doctor mentioned treating pancreatic cancer for sixteen years. What does that duration tell us?
Mimi
It tells us she's seen the disease evolve, seen what works and what doesn't. Sixteen years of watching patients die on schedule, essentially. So when something breaks that pattern, it lands differently than it would in a disease with better baseline outcomes.
Mark
Is daraxonrasib a cure?
Mimi
No. Nearly doubling survival is transformative in pancreatic cancer terms, but it's not a cure. It's a fundamental shift in what's possible, which in this context is enormous—but the disease is still lethal.
Mark
What should patients and families understand about what comes next?
Mimi
That this is real progress, but also that it's not yet in their hands. The trial happened. The results are striking. Now comes the slower work of approval, access, and integration into standard practice.
O Pulso
- Pancreatic cancer has resisted meaningful progress for decades, leaving oncologists with few tools and patients with grim prognoses measured in months.
- Results presented at ASCO in Chicago showed daraxonrasib nearly doubling survival time against standard chemotherapy — a finding that visibly moved specialists who have spent careers treating the disease.
- Unlike chemotherapy, which attacks cells broadly, daraxonrasib targets specific vulnerabilities in cancer cells, representing a fundamentally different therapeutic approach for a cancer that has long lacked one.
- The emotional response from oncologists — including tears from a physician with sixteen years of treating the disease — signals that this result crosses a threshold beyond routine clinical progress.
- Regulatory approval remains ahead, but the trajectory points toward a potential reshaping of treatment protocols and, for patients, the difference between incremental extension of life and genuine transformation of it.
For decades, pancreatic cancer has occupied a particular place in medicine's shadow — a disease so reliably fatal that oncologists have learned to measure hope in weeks rather than years. At a major oncology conference in Chicago, results from a trial of daraxonrasib, a targeted therapy developed by Revolution Medicines, offered something the field had not encountered before: patients living nearly twice as long as those on standard chemotherapy. In a disease where the five-year survival rate barely reaches ten percent, this is not merely a statistical milestone — it is a renegotiation of what medicine believes is possible.
Pancreatic cancer has long been a disease that wears down the doctors who treat it. With a five-year survival rate hovering around ten percent and standard chemotherapy offering only modest time, the field has operated under a quiet resignation — progress measured in weeks, hope carefully rationed.
That backdrop made the announcement at the American Society of Clinical Oncology conference in Chicago all the more striking. Researchers presented trial results for daraxonrasib, an experimental targeted drug from Revolution Medicines, showing that patients who received it lived nearly twice as long as those given standard chemotherapy. In a disease where every month carries weight, the finding was without precedent.
Rachna Shroff, an oncologist at the University of Arizona Cancer Center who has specialized in pancreatic cancer for sixteen years, learned of the results while in clinic in April. She wept. Speaking at a media briefing, she described the study as "incredibly impactful" — words that carried the particular relief of someone who had spent a career delivering difficult news and had finally been given something different to say.
Daraxonrasib is a targeted therapy, designed to exploit specific weaknesses in cancer cells rather than broadly poisoning them. This approach has already transformed outcomes in other cancers. That it may now do the same in pancreatic cancer — historically one of medicine's most resistant diseases — represents a shift in the entire therapeutic landscape.
Regulatory approval still lies ahead, and the distance between a trial result and a drug available to patients is real. But the response from the oncology community reflects something beyond statistics. Nearly doubling survival time is the difference between a patient who sees a grandchild graduate and one who does not — between a treatment that extends life and one that begins to transform it.
Pancreatic cancer has long been a disease that breaks the spirit of the doctors who treat it. The five-year survival rate hovers around 10 percent. Patients arrive with advanced disease. The standard response—chemotherapy—buys time but rarely transforms outcomes. This is the landscape against which a new finding lands with particular weight.
At the American Society of Clinical Oncology conference in Chicago, researchers presented results from a trial of daraxonrasib, an experimental targeted drug developed by Revolution Medicines. The numbers stopped people in their tracks. Patients who received daraxonrasib lived nearly twice as long as those given standard chemotherapy. In a disease where months matter, where families measure hope in increments, this represented something the field had not seen before.
Rachna Shroff, an oncologist at the University of Arizona Cancer Center who specializes in pancreatic cancer, was in clinic in April when word of the results reached her. She had been treating the disease for sixteen years—long enough to know the weight of its prognosis, the conversations she would need to have with patients about what was and was not possible. When she learned what daraxonrasib had accomplished, she wept. "This is such an incredibly impactful study for our patients," she said at a media briefing, her voice carrying the relief of someone who had waited a long time for something to change.
The significance of the finding lies partly in what it represents about the disease itself. Pancreatic cancer is ruthless. It spreads quickly, often undetected until it has already advanced. Standard chemotherapy—the baseline against which new treatments are measured—has been the best available option for decades. To nearly double survival time against that baseline is to fundamentally alter the conversation about what is possible.
Daraxonrasib works differently than traditional chemotherapy. It is a targeted drug, designed to attack specific vulnerabilities in cancer cells rather than poisoning cells broadly. This approach has transformed treatment in other cancers. In pancreatic cancer, where options have been limited and outcomes grim, the possibility of a targeted therapy that works represents a shift in the entire therapeutic landscape.
The path from a clinical trial result to a drug available to patients is not instantaneous. Regulatory approval remains ahead. But the emotional response from oncologists—the tears, the language of impact—reflects something deeper than statistical improvement. It reflects the weight of treating a disease where progress has been incremental, where survival gains are measured in weeks or months, where hope has been rationed. A nearly doubled survival time is not just a number. It is the difference between seeing a grandchild graduate and not. Between one more season and none. Between a treatment that extends life and one that transforms it.
Citações Notáveis
Having treated pancreatic cancer for 16 years, I actually started crying in the clinic. This is such an incredibly impactful study for our patients.— Rachna Shroff, oncologist at University of Arizona Cancer Center
Quer a matéria completa?
Leia o original em STAT ↗
Health & Medicine